These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

302 related articles for article (PubMed ID: 39008362)

  • 21. COVID-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of Pfizer/BioNTech and Moderna Vaccines.
    Meo SA; Bukhari IA; Akram J; Meo AS; Klonoff DC
    Eur Rev Med Pharmacol Sci; 2021 Feb; 25(3):1663-1669. PubMed ID: 33629336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cumulative Adverse Event Reporting of Anaphylaxis After mRNA COVID-19 Vaccine (Pfizer-BioNTech) Injections in Japan: The First-Month Report.
    Iguchi T; Umeda H; Kojima M; Kanno Y; Tanaka Y; Kinoshita N; Sato D
    Drug Saf; 2021 Nov; 44(11):1209-1214. PubMed ID: 34347278
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine - United States, December 14-23, 2020.
    ;
    MMWR Morb Mortal Wkly Rep; 2021 Jan; 70(2):46-51. PubMed ID: 33444297
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017.
    Yoon D; Kim JH; Lee H; Shin JY
    Yonsei Med J; 2020 Jul; 61(7):623-630. PubMed ID: 32608206
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex-disaggregated outcomes of adverse events after COVID-19 vaccination: A Dutch cohort study and review of the literature.
    Duijster JW; Lieber T; Pacelli S; Van Balveren L; Ruijs LS; Raethke M; Kant A; Van Hunsel F
    Front Immunol; 2023; 14():1078736. PubMed ID: 36793715
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adverse Events Following Immunization Associated with Coronavirus Disease 2019 Vaccination Reported in the Mobile Vaccine Adverse Events Reporting System.
    Jeon M; Kim J; Oh CE; Lee JY
    J Korean Med Sci; 2021 May; 36(17):e114. PubMed ID: 33942578
    [TBL] [Abstract][Full Text] [Related]  

  • 27. COVID-19 mRNA Vaccines: A Retrospective Observational Pharmacovigilance Study.
    Ferrara F; Mancaniello C; Varriale A; Sorrentino S; Zovi A; Nava E; Trama U; Boccellino M; Vitiello A
    Clin Drug Investig; 2022 Dec; 42(12):1065-1074. PubMed ID: 36274082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety Monitoring of Bivalent COVID-19 mRNA Vaccine Booster Doses Among Children Aged 5-11 Years - United States, October 12-January 1, 2023.
    Hause AM; Marquez P; Zhang B; Su JR; Myers TR; Gee J; Panchanathan SS; Thompson D; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2023 Jan; 72(2):39-43. PubMed ID: 36634021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Usefulness of Vaccine Adverse Event Reporting System for Machine-Learning Based Vaccine Research: A Case Study for COVID-19 Vaccines.
    Flora J; Khan W; Jin J; Jin D; Hussain A; Dajani K; Khan B
    Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897804
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Safety Monitoring of the Janssen (Johnson & Johnson) COVID-19 Vaccine - United States, March-April 2021.
    Shay DK; Gee J; Su JR; Myers TR; Marquez P; Liu R; Zhang B; Licata C; Clark TA; Shimabukuro TT
    MMWR Morb Mortal Wkly Rep; 2021 May; 70(18):680-684. PubMed ID: 33956784
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Herpetic Eye Disease After SARS-CoV-2 Vaccination: A CDC-VAERS Database Analysis.
    Singh RB; Parmar UPS; Ichhpujani P; Jeng BH; Jhanji V
    Cornea; 2023 Jun; 42(6):731-738. PubMed ID: 36706232
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Safety of Booster Doses of Coronavirus Disease 2019 (COVID-19) Vaccine in Pregnancy in the Vaccine Adverse Event Reporting System.
    Moro PL; Olson CK; Zhang B; Marquez P; Strid P
    Obstet Gynecol; 2022 Sep; 140(3):421-427. PubMed ID: 35926203
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety Monitoring of COVID-19 Vaccine Booster Doses Among Persons Aged 12-17 Years - United States, December 9, 2021-February 20, 2022.
    Hause AM; Baggs J; Marquez P; Abara WE; Olubajo B; Myers TR; Su JR; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Mar; 71(9):347-351. PubMed ID: 35239637
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety Monitoring of Pfizer-BioNTech COVID-19 Vaccine Booster Doses Among Children Aged 5-11 Years - United States, May 17-July 31, 2022.
    Hause AM; Baggs J; Marquez P; Myers TR; Su JR; Hugueley B; Thompson D; Gee J; Shimabukuro TT; Shay DK
    MMWR Morb Mortal Wkly Rep; 2022 Aug; 71(33):1047-1051. PubMed ID: 35980875
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Patient-reported outcomes of adverse events after COVID-19 vaccination in Nigeria: A mixed methods study.
    Ogar CK; Gilbert HN; Bloem LT; Leopold C; Bassi PU; Katagum YM; Osakwe AI; Opadeyi AO; Oreagba I; Mbo DND; Mantel-Teeuwisse AK; De Bruin ML
    Vaccine; 2024 Oct; 42(23):126196. PubMed ID: 39178765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Unpacking adverse events and associations post COVID-19 vaccination: a deep dive into vaccine adverse event reporting system data.
    Li Y; Lundin SK; Li J; Tao W; Dang Y; Chen Y; Tao C
    Expert Rev Vaccines; 2024; 23(1):53-59. PubMed ID: 38063069
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of co-administration of mRNA COVID-19 and seasonal inactivated influenza vaccines in the vaccine adverse event reporting system (VAERS) during July 1, 2021-June 30, 2022.
    Moro PL; Zhang B; Ennulat C; Harris M; McVey R; Woody G; Marquez P; McNeil MM; Su JR
    Vaccine; 2023 Mar; 41(11):1859-1863. PubMed ID: 36669964
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Determinants of COVID-19 vaccine-induced myocarditis.
    Rose J; Hulscher N; McCullough PA
    Ther Adv Drug Saf; 2024; 15():20420986241226566. PubMed ID: 38293564
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Analysis of hematologic adverse events reported to a national surveillance system following COVID-19 bivalent booster vaccination.
    Jacobs JW; Booth GS; Adkins BD
    Ann Hematol; 2023 Apr; 102(4):955-959. PubMed ID: 36795118
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A 1-year analysis of adverse events following COVID-19 vaccination in Lebanon: a retrospective study.
    Zeitoun A; Hallit S; Chehade S; Ibrahim A; Helali M; Allam C; Karam R
    J Pharm Policy Pract; 2023 Feb; 16(1):24. PubMed ID: 36810279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.